



Improving Knowledge and Awareness of Preventive Antibodies for Respiratory Syncytial Virus (RSV) for Infants and Young Children

References

- ABRYSVO® (Respiratory Syncytial Virus Vaccine) for injection, for intramuscular use. Package insert. Accessed December 13, 2025, <https://www.fda.gov/media/168889/download?attachment>
- American Academy of Pediatrics. AAP recommendations for the prevention of RSV disease in infants and children. Published August 19, 2025. Accessed December 13, 2025, <https://publications.aap.org/redbook/resources/25379/AAP-Recommendations-for-the-Prevention-of-RSV>
- American College of Obstetricians and Gynecologists. Maternal respiratory syncytial virus vaccination. Updated October 2025. Accessed December 13, 2025, <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccination>
- Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. *Nat Rev Microbiol*. 2019;17(4):233–245. doi:10.1038/s41579-019-0149-x
- BEYFORTUS (nirsevimab-alip) injection, for intramuscular use. Package insert. Updated August 2024. Accessed December 13, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761328s005lbl.pdf
- Bylsma LC, Suh M, Movva N, Fryzek JP, Nelson CB. Mortality among US infants and children under 5 years of age with respiratory syncytial virus and bronchiolitis: a systematic literature review. *J Infect Dis*. 2022;226(Suppl 2):S267–S281. doi:10.1093/infdis/jiac226
- Colosia A, Costello J, McQuarrie K, Kato K, Bertzos K. Systematic literature review of the signs and symptoms of respiratory syncytial virus. *Influenza Other Respir Viruses*. 2023;17(2):e13100. doi:10.1111/irv.13100
- Curns AT, Rha B, Lively JY, et al. Respiratory syncytial virus-associated hospitalizations among children <5 years old: 2016 to 2020. *Pediatrics*. 2024;153(3):e2023062574. doi:10.1542/peds.2023-062574
- Domachowske J, Madhi SA, Simoes EAF, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. *N Engl J Med*. 2022;386(9):892–894. doi:10.1056/NEJMc2112186
- Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. *N Engl J Med*. 2023;389(26):2425–2435. doi:10.1056/NEJMoa2309189
- ENFLONIA™ (clesrovimab-cfor) injection, for intramuscular use. Package insert. Updated June 2025. Accessed December 13, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761432s000lbl.pdf
- Fauroux B, Simoes EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. *Infect Dis Ther*. 2017;6(2):173–197. doi:10.1007/s40121-017-0151-4



Improving Knowledge and Awareness of Preventive Antibodies for Respiratory Syncytial Virus (RSV) for Infants and Young Children

Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(41):1115–1122. doi:10.15585/mmwr.mm7241e1

Fly JH, Eiland LS, Stultz JS. Nirsevimab: expansion of respiratory syncytial virus prevention options in neonates, infants, and at-risk young children. *Ann Pharmacother.* 2025;59(1):81–91. doi:10.1177/10600280241243357

Gantenberg JR, van Aalst R, Bhuma MR, et al. Risk analysis of respiratory syncytial virus among infants in the United States by birth month. *J Pediatric Infect Dis Soc.* 2024;13(6):317–327. doi:10.1093/jpids/piae042

Gantenberg JR, van Aalst R, Diakun DR, et al. Healthcare utilization during acute medically attended episodes of respiratory syncytial virus-related lower respiratory tract infection among infants in the United States. *PLoS One.* 2025;20(2):e0313573. doi:10.1371/journal.pone.0313573

Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. *N Engl J Med.* 2020;383(5):415–425. doi:10.1056/NEJMoa1913556

Hak SF, Venekamp RP, Billard MN, et al. Substantial burden of nonmedically attended RSV infection in healthy-term infants: an international prospective birth cohort study. *J Infect Dis.* 2024;229(Supplement_1):S40–S50. doi:10.1093/infdis/jiad477

Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus - United States, 2017-2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(14):355–361. doi:10.15585/mmwr.mm7214a1

Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. *N Engl J Med.* 2022;386(9):837–846. doi:10.1056/NEJMoa2110275

Hutton DW, Prosser LA, Rose AM, et al. Cost-effectiveness of maternal vaccination to prevent respiratory syncytial virus illness. *Pediatrics.* 2024;154(6):2024066481. doi:10.1542/peds.2024-066481

Hutton DW, Prosser LA, Rose AM, et al. Cost-effectiveness of nirsevimab for respiratory syncytial virus in infants and young children. *Pediatrics.* 2024;154(6):2024066461. doi:10.1542/peds.2024-066461

Jasset OJ, Lopez Zapana PA, Bahadir Z, et al. Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth. *Am J Obstet Gynecol.* 2025;232(6):554 e1–554 e15. doi:10.1016/j.ajog.2024.10.053

Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(34):920–925. doi:10.15585/mmwr.mm7234a4



Improving Knowledge and Awareness of Preventive Antibodies for Respiratory Syncytial Virus (RSV) for Infants and Young Children

Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. *Cureus*. 2023;15(3):e36342. doi:10.7759/cureus.36342

Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. *N Engl J Med*. 2023;388(16):1451–1464. doi:10.1056/NEJMoa2216480

Kirolos N, Mtaweh H, Datta RR, et al. Risk factors for severe disease among children hospitalized with respiratory syncytial virus. *JAMA Netw Open*. 2025;8(4):e254666. doi:10.1001/jamanetworkopen.2025.4666

Lefferts B, Bressler S, Keck JW, et al. Nirsevimab effectiveness against medically attended respiratory syncytial virus illness and hospitalization among Alaska Native children - Yukon-Kuskokwim Delta region, Alaska, October 2023-June 2024. *MMWR Morb Mortal Wkly Rep*. 2024;73(45):1015–1021. doi:10.15585/mmwr.mm7345a1

Manzoni P, Viora E, Lanari M, et al. Maternal risk factors for respiratory syncytial virus lower respiratory tract infection in otherwise healthy preterm and term infants: a systematic review and meta-analysis. *Pediatr Infect Dis J*. 2024;43(8):763–771. doi:10.1097/INF.0000000000004387

Moline HL, Tannis A, Toepfer AP, et al. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - New Vaccine Surveillance Network, October 2023-February 2024. *MMWR Morb Mortal Wkly Rep*. 2024;73(9):209–214. doi:10.15585/mmwr.mm7309a4

Munro APS, Martinon-Torres F, Drysdale SB, Faust SN. The disease burden of respiratory syncytial virus in infants. *Curr Opin Infect Dis*. 2023;36(5):379–384. doi:10.1097/QCO.0000000000000952

Munro APS, Drysdale SB, Cathie K, et al. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. *Lancet Child Adolesc Health*. 2025;9(6):404-412. doi:10.1016/S2352-4642(25)00102-6

Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. *J Infect Dis*. 2018;217(9):1356–1364. doi:10.1093/infdis/jiy056

Okubo Y, Uda K, Yoshikawa Y, Ogimi C, Nakabayashi Y, Ito K. Nationwide epidemiology and outpatient healthcare resource use of children with respiratory syncytial virus from 2005 to 2021. *J Pediatric Infect Dis Soc*. 2025;14(1):pia115. doi:10.1093/jpids/piae115

Oppenlander KE, Chung AA, Clabaugh D. Respiratory syncytial virus bronchiolitis: rapid evidence review. *Am Fam Physician*. 2023;108(1):52–57.



Improving Knowledge and Awareness of Preventive Antibodies for Respiratory Syncytial Virus (RSV) for Infants and Young Children

Patton ME, Moline HL, Whitaker M, et al. Interim evaluation of respiratory syncytial virus hospitalization rates among infants and young children after introduction of respiratory syncytial virus prevention products - United States, October 2024-February 2025. *MMWR Morb Mortal Wkly Rep.* 2025;74(16):273–281. doi:10.15585/mmwr.mm7416a1

Pecenka C, Sparrow E, Feikin DR, et al. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children. *Lancet.* 2024;404(10458):1157–1170. doi:10.1016/S0140-6736(24)01699-4

Radcliffe CR, Akkawi G, Carson RA. Practical application of nirsevimab recommendations for infants and toddlers. *J Pediatr Health Care.* 2024;S0891-5254(24):00373–0. doi:10.1016/j.pedhc.2024.11.005

Rosas-Salazar C, Chirkova T, Gebretsadik T, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. *Lancet.* 2023;401(10389):1669-1680. doi:10.1016/S0140-6736(23)00811-5

Simões EAF, Pahud BA, Madhi SA, et al. Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial. *Obstet Gynecol.* 2025;145(2):157-167. doi:10.1097/AOG.0000000000005816

Sommer C, Resch B, Simões EAF. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. *Open Microbiol J.* 2011;5:144–154. doi:10.2174/1874285801105010144

Son M, Riley LE, Staniczenko AP, et al. Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes. *JAMA Netw Open.* 2024;7(7):e2419268. doi:10.1001/jamanetworkopen.2024.19268

Sumsuzzman DM, Wang Z, Langley JM, Moghadas SM. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. *Lancet Child Adolesc Health.* 2025;9(6):393-403. doi:10.1016/S2352-4642(25)00093-8

Tran PT, Nduaguba SO, Wang Y, et al. Economic burden of medically attended respiratory syncytial virus infections among privately insured children under 5 years of age in the USA. *Influenza Other Respir Viruses.* 2024;18(7):e13347. doi:10.1111/irv.13347

Wang X, Li Y, Shi T, et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. *Lancet.* 2024;403(10433):1241–1253. doi:10.1016/S0140-6736(24)00138-7

Wilkins D, Wählby Hamrén U, Chang Y, et al. RSV neutralizing antibodies following nirsevimab and palivizumab dosing. *Pediatrics.* 2024;154(5):2024067174. doi:10.1542/peds.2024-067174

Xu H, Aparicio C, Wats A, et al. Estimated effectiveness of nirsevimab against respiratory syncytial virus. *JAMA Netw Open.* 2025;8(3):e250380. doi:10.1001/jamanetworkopen.2025.0380



Improving Knowledge and Awareness of Preventive Antibodies for Respiratory Syncytial Virus (RSV) for Infants and Young Children

Zambrano LD, Simeone RM, Newhams MM, et al. Nirsevimab effectiveness against intensive care unit admission for respiratory syncytial virus in infants - 24 states, December 2024-April 2025. *MMWR Morb Mortal Wkly Rep.* 2025;74(37):580-588. doi:10.15585/mmwr.mm7437a1

Zar HJ, Cacho F, Kootbodien T, et al. Early-life respiratory syncytial virus disease and long-term respiratory health. *Lancet Respir Med.* 2024;12(10):810–821. doi:10.1016/S2213-2600(24)00246-7

Zar HJ, Simões EAF, Madhi SA, et al. Clesrovimab for prevention of RSV disease in healthy infants. *N Engl J Med.* 2025;393(13):1292-1303. doi:10.1056/NEJMoa2502984